An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.

The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.

An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.